Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.

Also called NCT01850615

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 323 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01850615
  • EudraCT 2012-005583-10
  • CTRI CTRI/2014/01/004289
Main results
  • Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3) Diabetes, obesity & metabolism, 2017-10 DOI, PubMed 28345792, PMC5637905 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, India, Mexico, Romania, Slovenia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01850615. Randomized; no masking; primary purpose treatment. Start 2013-09-23 (actual); primary completion 2014-11-17 (actual). Results posted on 2018-01-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
Acronym
onset® 3
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Faster-acting insulin aspart
Intervention (Drug)
basal insulin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01850615
Content hash
1f74faa0008f19637683aea58a7f2317f704b8b115d1fb6e2f1b6daa2fc33930